Attix Pharmaceuticals Recalls Vidarbine Monophosphate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Vidarbine Monophosphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: FDA Class II recall involving a high-risk allergen (penicillin) cross-contamination in a pharmaceutical ingredient, which poses a significant risk of severe allergic reactions or anaphylaxis to sensitive individuals, meeting the criteria for Severe severity.
Plain-English summary
Attix Pharmaceuticals is recalling all lots of Vidarbine Monophosphate active pharmaceutical ingredient (API) that were repackaged and distributed between January 5, 2012, and February 12, 2015. The product was packaged in varying grams or kilograms in bags or drums. The recall is being conducted because the API was repackaged in a facility that also handled penicillin products without adequate separation, creating a potential for cross-contamination with penicillin.
The affected product was distributed nationwide to compounding pharmacies and research organizations. No specific illness or injury reports are mentioned in the source text, but the presence of penicillin contamination poses a significant risk to individuals with penicillin allergies.
Compounding pharmacies and research organizations that received this product should stop using it immediately and contact Attix Pharmaceuticals for instructions on return or disposal. Consumers should not use any Vidarbine Monophosphate API from this source and should consult their healthcare provider if they have concerns about potential exposure.
The recalled product
- Product
- Vidarbine Monophosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
- Manufacturer
- Attix Pharmaceuticals
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots repackaged and distributed between 01/05/12 to 02/12/15
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 470 recalled by Attix Pharmaceuticals under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 470 products in this recall →Related recalls
Same manufacturer · Attix Pharmaceuticals
See all →- SevereAttix Pharmaceuticals Recalls Idebenone Due to Penicillin Cross Contamination Risk
FDA (Drugs) · 2015-04-29
- SevereAttix Pharmaceuticals Recalls Methylprednisolone Base Due to Penicillin Cross-Contamination Risk
FDA (Drugs) · 2015-04-29
- SevereCarbazochrome API Recalled for Potential Penicillin Cross Contamination
FDA (Drugs) · 2015-04-29
- SevereAttix Pharmaceuticals Recalls Cidofovir Dihydrate Due to Penicillin Cross-Contamination Risk
FDA (Drugs) · 2015-04-29
- SevereAttix Pharmaceuticals Recalls Pheniramine Maleate Due to Penicillin Cross-Contamination Risk
FDA (Drugs) · 2015-04-29
Same hazard · allergen penicillin
See all →- HighFreedom Pharmaceuticals Recalls Domperidone API Due to Penicillin Cross-Contamination
FDA (Drugs) · 2016-01-20
- HighLife Science Pharmacy Recalls TRI-EST Gels Due to Penicillin Contamination
FDA (Drugs) · 2015-12-09
- HighLife Science Pharmacy Recalls Compounded Estriol Suppositories Due to Penicillin Contamination
FDA (Drugs) · 2015-12-09
- HighLife Science Pharmacy Recalls Compounded Estriol Vaginal Creams
FDA (Drugs) · 2015-12-09
- HighLife Science Pharmacy Recalls Compounded Estriol Gels Due to Penicillin Contamination
FDA (Drugs) · 2015-12-09